# Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.

> **NCT07009925** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 38 (estimated)

## Conditions studied

- Squamous Cell Lung Cancer

## Interventions

- **DRUG:** Ivonescimab 20mg/kg intravenous every 3 weeks

## Key facts

- **NCT ID:** NCT07009925
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06
- **Primary completion:** 2027-05
- **Final completion:** 2028-05
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07009925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07009925, "Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07009925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*